ClinicalTrials.gg
RecruitingNCT07462546Updated Mar 25, 2026

Transcranial Doppler for Internal Carotid Artery Stenting (TCD-ICAS)

An interventional study of Transcranial Doppler in Artery Stenosis, sponsored by General Hospital of Shenyang Military Region. Recruiting at 1 site in China. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by General Hospital of Shenyang Military Region · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
232
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Constriction, Pathologic with a site in China — 37 open to participants now, 40 under way, 3 of them phase 3. Constriction, Pathologic · China.

Planned enrollment
16th of 56
232 · median 145
Started
2026
with 7 others
No phase
48 of 81
21 open now
Primary completion
2026-11
later than 15 of 39 live
Registered
76th of 81
by date

Among the 81 studies in Constriction, Pathologic with a site in China, this one is the 16th largest by planned enrollment of the 56 interventional ones that give a count, is one of 8 that started in 2026, is one of 48 with no phase, reaches primary completion later than 15 of the 39 other live ones, and was the 76th registered.

Constriction, Pathologic

457 studies on the registry are indexed under Constriction, Pathologic; 110 are open to participants now.

Browse Constriction, Pathologic studies →

Open to participants now

37 of the 81 studies in Constriction, Pathologic with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 67 Constriction, Pathologic studies recruiting now, 34 (51%) set no upper age limit and 14 (21%) stop at 75 or younger; 8 take children under 18; 1 takes healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Constriction, Pathologic with a site in China, or all of them as a file.
02

Study summary

Carotid artery stenting (CAS) prevents stroke but carries risks of perioperative cerebral embolism. Transcranial Doppler (TCD) ultrasound can detect microemboli during CAS and may offer therapeutic benefits through ultrasound-enhanced thrombolysis. Trials like SONOBUSTER and SONOBIRDIE suggest TCD reduces new brain infarctions during carotid procedures. The TCD-ICAS trial will investigate whether TCD application during and after CAS reduces perioperative cerebral emboli and improves outcomes.

03

Conditions studied

  • Artery Stenosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 40 years old;
  • Patients with severe stenosis of the internal carotid artery;
  • Planned for carotid artery stent;
  • Modified Rankin Scale score ≤ 2;
  • The subject has adequate temporal bone windows to undergo TCD, and the blood flow signal of the middle cerebral artery is detectable.;
  • Signed by patient or their legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  • Comorbid conditions with severe infections or severe diseases of the liver, kidney, hematopoietic system, endocrine system, etc.;
  • Occurrence of intracranial hemorrhage (cerebral parenchymal hemorrhage, subarachnoid hemorrhage, subdural/epidural hemorrhage) within 90 days prior to enrollment;
  • Severe hematological disorders or significant coagulation abnormalities;
  • Pregnant or breastfeeding women;
  • Participation in another clinical trial within the past 3 months or ongoing participation;
  • Any other circumstances deemed by the investigator as unsuitable for participation in this clinical study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
232 participants (estimated)

Study arms

  • Experimental
    TCD group

    Device: Transcranial Doppler

  • No intervention
    Control group

Interventions

  • DeviceTranscranial Doppler

    TCD treatment (1.6 MHz, 0.274 MPa) from femoral artery puncture until 30-60 minutes after procedure completion

06

What researchers measure

Primary outcomes

  1. number of new Magnetic Resonance Imaging - Diffusion Weighted Imaging lesions

    Time frame: 24 (±8) hours

Secondary outcomes

  1. total volume of new Magnetic Resonance Imaging - Diffusion Weighted Imaging lesions

    Time frame: 30±3 days

  2. number of new Magnetic Resonance Imaging - Diffusion Weighted Imaging lesions >0.5 mL

    Time frame: 30±3 days

  3. composite of ischemic stroke, transient ischemic attack (TIA), or death

    Time frame: 30±3 days

  4. intracranial hemorrhage on neuroimaging

    Time frame: 24 (±8) hours

  5. serious adverse events

    Time frame: 24 (±8) hours

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Nov 2026, 8 months after the start.

Of 90 non-industry interventional studies with no phase under Constriction, Pathologic, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 49. This study's planned 8 months is below that.

Counting every sponsor, half of 133 studies reached it within 36 months; a quarter within 18 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2026
First posted
Mar 10, 2026
StartActual
Mar 24, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07462546
Lead sponsor
General Hospital of Shenyang Military Region
Responsible party
Hui-Sheng Chen (Director, General Hospital of Shenyang Military Region) — Principal investigator
First posted
Mar 10, 2026
Start date
Mar 24, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Mar 25, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion